Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:DYN NASDAQ:ENTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$4.83+6.7%$5.57$1.85▼$7.18$786.12M1.182.55 million shs1.40 million shsDYNDyne Therapeutics$19.06+5.5%$18.25$8.06▼$25.00$3.14B1.091.95 million shs2.68 million shsENTAEnanta Pharmaceuticals$12.41+2.8%$13.39$6.43▼$17.15$360.48M0.97188,913 shs113,143 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-2.59%-13.08%-13.24%-16.61%+85.25%DYNDyne Therapeutics-3.52%+0.84%+4.51%-1.20%+30.75%ENTAEnanta Pharmaceuticals+5.51%+6.34%-9.99%-4.96%+65.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$4.83+6.7%$5.57$1.85▼$7.18$786.12M1.182.55 million shs1.40 million shsDYNDyne Therapeutics$19.06+5.5%$18.25$8.06▼$25.00$3.14B1.091.95 million shs2.68 million shsENTAEnanta Pharmaceuticals$12.41+2.8%$13.39$6.43▼$17.15$360.48M0.97188,913 shs113,143 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-2.59%-13.08%-13.24%-16.61%+85.25%DYNDyne Therapeutics-3.52%+0.84%+4.51%-1.20%+30.75%ENTAEnanta Pharmaceuticals+5.51%+6.34%-9.99%-4.96%+65.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.43Hold$16.00234.31% UpsideDYNDyne Therapeutics 2.94Moderate Buy$35.0082.92% UpsideENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2967.10% UpsideCurrent Analyst Ratings BreakdownLatest DYN, ANNX, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026DYNDyne Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/13/2026DYNDyne Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$23.00 ➝ $24.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.004/20/2026ANNXAnnexon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DYNDyne Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ENTAEnanta Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026ENTAEnanta Pharmaceuticals Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.003/20/2026ANNXAnnexon Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/ADYNDyne TherapeuticsN/AN/AN/AN/A$6.81 per shareN/AENTAEnanta Pharmaceuticals$65.32M5.40N/AN/A$3.03 per share4.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)DYNDyne Therapeutics-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)ENTAEnanta Pharmaceuticals-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)Latest DYN, ANNX, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026DYNDyne Therapeutics-$0.7723-$0.73+$0.0423-$0.73N/AN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A3/30/2026Q4 2025ANNXAnnexon-$0.32-$0.28+$0.04-$0.28$3.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35DYNDyne Therapeutics0.1719.9219.92ENTAEnanta PharmaceuticalsN/A3.843.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ADYNDyne Therapeutics96.68%ENTAEnanta Pharmaceuticals94.99%Insider OwnershipCompanyInsider OwnershipANNXAnnexon10.31%DYNDyne Therapeutics9.46%ENTAEnanta Pharmaceuticals11.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million146.95 millionOptionableDYNDyne Therapeutics100165.31 million149.68 millionOptionableENTAEnanta Pharmaceuticals16029.08 million25.74 millionOptionableDYN, ANNX, and ENTA HeadlinesRecent News About These CompaniesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by BrokeragesJune 17 at 4:21 AM | americanbankingnews.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026May 11, 2026 | pharmiweb.comPEnanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue EstimatesMay 11, 2026 | zacks.comEnanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?May 7, 2026 | zacks.comEnanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of UrticariaApril 13, 2026 | pharmiweb.comPEnanta Pharmaceuticals Announces Public Stock OfferingApril 11, 2026 | msn.comEnanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory ...April 7, 2026 | finanznachrichten.deEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID ...April 7, 2026 | finance.yahoo.comEnanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)March 30, 2026 | finance.yahoo.comEnanta (NASDAQ:ENTA) Biotech Momentum Builds Across Nasdaq IndexMarch 27, 2026 | kalkinemedia.comKEnanta Advances Federal Circuit Appeal in Paxlovid Patent CaseMarch 26, 2026 | tipranks.comEnanta Pharmaceuticals (ENTA) Gets a Buy from J.P. MorganMarch 8, 2026 | theglobeandmail.comEnanta Pharmaceuticals to Present at The Citizens Life Sciences ConferenceMarch 3, 2026 | finance.yahoo.comWhat Makes Enanta Pharmaceuticals (ENTA) a New Buy StockFebruary 12, 2026 | zacks.comWhy Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.97%February 11, 2026 | aaii.comAEnanta Pharmaceuticals: Fiscal Q1 Earnings SnapshotFebruary 10, 2026 | finance.yahoo.comEnanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue EstimatesFebruary 9, 2026 | zacks.comEnanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comEnanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 OutlookJanuary 8, 2026 | pharmiweb.comPEnanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDYN, ANNX, and ENTA Company DescriptionsAnnexon NASDAQ:ANNX$4.82 +0.31 (+6.75%) As of 03:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Dyne Therapeutics NASDAQ:DYN$19.06 +0.99 (+5.50%) As of 03:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$12.41 +0.34 (+2.83%) As of 03:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Could a Tesla-SpaceX Merger Be Closer Than Investors Think? After SpaceX, Amazon Could Be The Next Best Space Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
